Results 191 to 200 of about 1,182,951 (299)

Efficacy and Safety of Xeligekimab Compared to Other IL-17A Inhibitors for Chinese Patients with Moderate-to-severe Plaque Psoriasis: A Matching-adjusted Indirect Comparisons. [PDF]

Acta Derm Venereol
Ding Y, Liu W.
europepmc   +1 more source

Batavia City School District and Batavia Administrators Association (2015) [PDF]

, 2015

core   +1 more source

Insights into a long life without cancer: The case of the bowhead whale

Molecular Oncology, EarlyView.
Long‐lived, large‐bodied organisms have evolved powerful anticancer mechanisms that preserve cellular and tissue integrity across extended lifespans. A recent study by Firsanov et al. shows that greater genome stability is a key factor underlying the remarkable longevity and cancer resistance of one such species, the bowhead whale.
Inés Paniagua, Johanna A. Joyce
wiley   +1 more source

Author Correction: Single-cell multi-omic detection of DNA methylation and histone modifications reconstructs the dynamics of epigenomic maintenance. [PDF]

Nat Methods
Geisenberger C, van den Berg J, van Batenburg V, de Barbanson B, Lyubimova A, Verity-Legg J, Chen X, Liu Y, Song CX, de Ridder J, van Oudenaarden A.   +10 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

<i>C. elegans</i> Spastin/<i>spas-1</i> Is Required for Axon Regeneration and Maintenance. [PDF]

eNeuro
Howell MC, El Bejjani RM.
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma. [PDF]

Blood Adv
Wang Y, Larson MC, Hwang SR, Villa D, Kugathasan L, Kumar A, Joseph A, Brooks TR, Hill BT, Bond DA, Maddocks KJ, Nizamuddin IA, Kahl BS, Danilov A, Argao C, Ruan J, Ryan CE, Merryman RW, Grover NS, Khan NB, Ouchveridze E, Tun AM, Ayyappan S, Mou E, Pongas GN, Lossos IS, Harris ZI, Munoz JL, Young P, Portell CA, Baidoun F, Alhaj Moustafa M, Reagan PM, Banaszak LG, Pophali PA, Velayati A, Greenwell IB, Gerber D, Jain P, Wang ML, Narkhede MS, Mehta A, Stack AC, Messmer MR, Bhansali RS, Barta SK, Moyo TK, Ghosh N, Kamdar MK, Anna J, Stanisic AV, Karmali R, Maurer MJ, Cerhan JR, Cohen JB, Martin P.   +55 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Comparison of two omalizumab dose-reduction strategies in patients with chronic spontaneous urticaria during the control phase: standard dose maintenance therapy versus extended interval dose reduction. [PDF]

Am J Transl Res
Zhang L, Chen J.
europepmc   +1 more source